Newsroom | 4368 results

CAMBRIDGE, England--(BUSINESS WIRE)--Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina’s appointment as a Director forms part of the Company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform. K...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, today announced that its parent company, MEDIPOST Co., Ltd., has closed on $140 million in funding. The investment, led by Skylake Equity Partners and Crescendo Equity Partners, with participation from Korea’s leading growth equity fund, was completed at the parent-company level and will accelerate the co...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio announces $250M in aggregate financing to support launch readiness leading up to the Orca-T® PDUFA date of April 6, 2026....

SAN FRANCISCO--(BUSINESS WIRE)--Cytotherapy article shows Ossium’s off-the-shelf organ donor bone marrow enables rapid, consistent alloHCT with strong early clinical data....

ÉDIMBOURG, Écosse--(BUSINESS WIRE)--RoslinCT, une organisation mondiale de développement et de fabrication sous contrat (CDMO) spécialisée dans les thérapies cellulaires avancées, et BOOST Pharma, une biotech de phase clinique développant des thérapies cellulaires pionnières pour les maladies squelettiques pédiatriques rares, annoncent aujourd’hui un partenariat de fabrication stratégique pour soutenir le développement de la thérapie cellulaire de BOOST Pharma, BT-101, pour le traitement des no...

EDIMBURGO, Escocia--(BUSINESS WIRE)--RoslinCT, una organización internacional dedicada al desarrollo y la fabricación por contrato (CDMO) especializada en terapias celulares avanzadas, y BOOST Pharma, una empresa biotecnológica en fase clínica que desarrolla terapias celulares pioneras para enfermedades óseas pediátricas raras, han anunciado hoy un acuerdo estratégico de fabricación para impulsar el desarrollo de la terapia celular BT-101 de BOOST Pharma, destinada al tratamiento de bebés con o...

EDINBURGH, Schottland--(BUSINESS WIRE)--RoslinCT, ein weltweit tätiges Auftragsentwicklungs- und Produktionsunternehmen (CDMO) mit Spezialisierung auf fortschrittliche Zelltherapien, und BOOST Pharma, ein Biotechnologieunternehmen im klinischen Stadium, das erstklassige Zelltherapien für seltene pädiatrische Skeletterkrankungen entwickelt, gaben heute eine strategische Produktionspartnerschaft bekannt, um die Entwicklung der Zelltherapie BT-101 von BOOST Pharma zur Behandlung von Säuglingen mit...

SAN FRANCISCO & KYOTO, Japan--(BUSINESS WIRE)--One Genomics, an AI-focused genomics company advancing de-aging research and co-founded by Harvard Professor George Church alongside former Harvard and MIT research fellows and alumni, today announced a strategic research collaboration agreement with the CiRA Foundation to advance precision genome engineering technologies. Established by Kyoto University, the CiRA Foundation is a leading induced pluripotent stem (iPS) cell manufacturing and researc...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cellino and Polyphron Partner to Make Personalized Tissue Replacement Routine...

ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PEP Biologic™ for the treatment of diabetic foot ulcers (DFU) under IND 019567. FDA Fast Track designation is designed to facilitate the development and expedite the review of drugs an...